Market Closed -
Nasdaq
01:30:00 01/06/2024 am IST
5-day change
1st Jan Change
39.25
USD
-3.68%
-3.35%
-34.43%
Safety of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials
September 30, 2021 at 09:32 pm IST
Safety of intravitreal pegcetacoplan in geographic atrophy: results from the DERBY and OAKS trials
Charles Wykoff, Jeffrey Heier, Rishi Singh, Nathan Steinle, David Boyer, Jordi Monés, Giovanni Staurenghi, Frank G. Holz, Caleb Bliss, Pascal Deschatelets, Federico Grossi, Cedric Francois, Ramiro Ribeiro
30 September 2021
Retina Society 2021, Chicago, USA
Disclosures
Dr. Wykoff has the following Disclosures:
Consulting: AbbVie, Adverum, Aerie Pharmaceuticals, Allergan, Allgenesis, Alnylam, Annexon, Apellis, Arrowhead Pharmaceuticals, Bausch + Lomb, Bayer, Bionic Vision Technologies, Chengdu Kanghong Biotechnologies (KHB), Clearside Biomedical, EyePoint Pharmaceuticals, Genentech, Gyroscope, IVERIC Bio, Janssen, Kato Pharmaceuticals, Kodiak Sciences, Long Bridge Medical, NGM Biopharmaceuticals, Novartis, OccuRx, Ocular Therapeutix, ONL Therapeutics, Opthea Limited, Palatin, Perfuse Therapeutics, PolyPhotonix, RecensMedical, Regeneron, RegenXBio, Roche, Surrozen, Takeda, Valo, Verana Health, Vitranu
Research: Adverum, Aerie Pharmaceuticals, Aldeyra, Alimera Sciences, Alkahest, Allergan, Amgen, Annexon, Apellis , Asclepix, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Gemini, Genentech, Graybug Vision, Gyroscope, IONIS Pharmaceutical, iRENIX, IVERIC bio, Kodiak Sciences, LMRI, Nanoscope, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Opthea, Oxurion, RecensMedical, Regeneron, RegenXBio, Roche, SamChunDang Pharm, Taiwan Liposome Company, Xbrane BioPharma
Ownership/Stock: ONL Therapeutics, PolyPhotonix, RecensMedical, Visgenx
Study funded by Apellis Pharmaceuticals
Outline
Patient Disposition and Drug Exposure
Overall AEs and SAEs
Cases of Intraocular Inflammation
Cases of Infectious Endophthalmitis
Cases of Exudative AMD
AMD=age-related macular degeneration; AE=adverse event; SAE=serious AE.
Patient disposition
OAKS
DERBY
PM
PEOM
Sham
PM
PEOM
Sham
Pooled
Pooled
(N=213)
(N=212)
(N=206)
(N=208)
(N=212)
(N=207)
Completed study through
184 (86.4%)
190 (89.6%)
191 (90.1%)
183 (88.8%)
188 (90.4%)
179 (86.5%)
Month 12, n (%)
Discontinued study prior
29
(13.6%)
22
(10.4%)
21 (9.9%)
23 (11.2%)
20 (9.6%)
28 (13.5%)
to Month 12, n (%)
Reason for discontinuation
Consent withdrawal
14 (6.6%)
11 (5.2%)
9 (4.2%)
15 (7.3%)
10 (4.8%)
15 (7.2%)
Death
7
(3.3%)
3
(1.4%)
4 (1.9%)
5 (2.4%)
0
3 (1.4%)
Adverse event
3 (1.4%)
5 (2.4%)
2 (0.9%)
1 (0.5%)
4 (1.9%)
5 (2.4%)
COVID-19 impact
3
(1.4%)
2
(0.9%)
5 (2.4%)
1 (0.5%)
6 (2.9%)
5 (2.4%)
Lost to follow-up
2
(0.9%)
1
(0.5%)
1 (0.5%)
1 (0.5%)
0
0
N=number of patients; PM=pegcetacoplan monthly; PEOM=pegcetacoplan every other month.
This is an excerpt of the original content. To continue reading it, access the original document here .
Attachments
Original document
Permalink
Disclaimer
Apellis Pharmaceuticals Inc. published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 30 September 2021 16:01:02 UTC .
Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target
31/05
MT
Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases
24/05
MT
Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
24/05
CI
Wells Fargo Adjusts Price Target on Apellis Pharmaceuticals to $48 From $57, Maintains Equal-Weight Rating
24/05
MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
14/05
Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street
14/05
MT
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
14/05
CI
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing
10/05
MT
UBS Adjusts Price Target on Apellis Pharmaceuticals to $85 From $89, Maintains Buy Rating
08/05
MT
Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $50 From $57, Maintains Neutral Rating
08/05
MT
Transcript : Apellis Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
07/05
Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises
07/05
MT
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q1 Revenue $172.3M
07/05
MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
07/05
CI
Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating
29/04
MT
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
26/04
MT
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency
26/04
CI
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating
17/04
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing
10/04
MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM
08/04
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing
21/03
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing
20/03
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing
15/03
MT
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing
12/03
MT
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024
11/03
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Companyâs approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
More about the company
Last Close Price
39.25
USD
Average target price
79.5
USD
Spread / Average Target
+102.55%
Consensus
1st Jan change
Capi.
-34.43% 476.36Cr -2.29% 8.99TCr -3.95% 3.76TCr -13.07% 3.28TCr +63.05% 2.65TCr -22.14% 1.43TCr -7.96% 1.3TCr -9.33% 1.19TCr -46.33% 1.08TCr +5.77% 911.12Cr
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1